Dr Greg Wilson

Interview by @patientpowereu regarding Liver Directed Therapy- #SIRT, #ChemoSat for Liver Metastases: youtube.com/watch?v=x1J567…

New gameshow just dropped.

@eleanor_leech @bmj_latest Yes of course. Very few women do private practice. It’s mostly a choice however.

@uk_oncologist @bmj_latest Do you think childcare falls more on the women too? It’s hard enough juggling that with your main NHS job without also working on the side.

Only 6% of surgeons working in the private sector are women, new research has found. Researchers noted the striking difference in the gender balance of the workforce compared with the NHS where 16.9% of surgeons are women bmj.com/content/392/bm…

@DocEmUK That’s very interesting. Something similar is happening in hospitals where consultants are dealing with exclusively extremely complex cases where anything more straightforward goes to different clinics with more easily adhered to protocols. Mentally it’s far more tiring.

One problem with GP is the complexity now the straightforward stuff is filtered elsewhere (pill checks to community pharmacy for example). I’m 2.5h in and have brain-fry. Taking a couple of mins to clear my head. This is absolutely what we trained for, but not at this volume or with this extent of rejection of input from other services. Patients are left with nowhere to go and we are clutching at straws in things we can offer - not infrequently little more than a sympathetic chat and acknowledgment of their suffering.

@GeniusGTX Excellent thread!

A "Paradox" is a statement that seems contradictory but actually contains a hidden truth. Once you see them, your worldview changes forever. Here are my 10 favorite mind-bending paradoxes that will upgrade your thinking & decision making: 🧵 1. The Paradox of Choice

@1919Ceepee @trentconsultant I think it’s both, isn’t it? In reality it is the only seller of medical services as well as the only buyer. The private sector is tiny in comparison.

@trentconsultant For the 10000th time - the NHS is a monopsony, not a monopoly. No wonder no one can take this crap seriously.

Medical students are finishing with £100k debts and we have a monopoly employer and controller of medical student places. You cannot abrogate responsibility as a government when you control all of those factors. Unless you want medicine to be a deeply unpopular career of course.

@METUPUKorg Thanks Lisa 🙏

@METUPUKorg RIP Jo ❤️

It is with profound sadness that we share the heartbreaking news that our beloved founder, Jo Taylor, died early on Monday morning surrounded by her husband Jeff, and two children, Regan and Faron.   Jo was a tireless advocate, a fearless campaigner and a beacon of hope for those living with metastatic breast cancer. Diagnosed with primary breast cancer in 2007 and with metastatic breast cancer in 2014, Jo dedicated her life to changing the narrative around MBC. She founded METUPUK and created the powerful #BusyLivingWithMets movement to show the world that people with MBC are living, thriving and worth the investment.    Jo’s legacy is one of courage and unwavering determination. Her work has touched countless lives both here in the UK and around the world. From her advocacy and public speaking to the creation of the red flag signs and symptoms infographics, she undoubtedly paved the way to empower others to find their voice.    She championed change with unwavering resolve and spoke with unflinching honesty. Jo’s voice lives on; her messages echo louder than ever: we demand change.    Our thoughts are with Jo’s family, friends, and the entire MBC community. She will be deeply missed and absolutely never forgotten.    She had the heart of a lioness. Rest in power, Jo 💔    #JoTaylor #METUPUK #LegacyOfChange #MetastaticBreastCancer #MBCAdvocate #Stage4NeedsMore #BreastCancerAwareness #METUPUKCampaign #InMemory #PatientAdvocacy #KeepTalkingMBC #HonouringJoTaylor #WomenWhoInspire #NeverStopFighting

Presentation can be found here: congress-collections.medengine.com/dqt25av016885/ @DelcathSystems @ACureInSight1 @MRFCureOM @OcuMelUK #LiverDirectedTherapy #DCTH

The results were excellent. Response rate when combining ChemoSat with Ipi/Nivo was 76% with 13% patients having complete response (complete remission on scan). Median PFS 12.8m v 8.3m. Median OS 23.1m v 19.6.

The Chopin randomised phase 2 trial was presented at ESMO 2025 conference by Dr Ellen Kapiteijn from Leiden in The Netherlands. PHP (ChemoSat/Hepzato) with Ipi/Nivo significantly better than without for #metastatic uveal melanoma in the liver.

@DrRishabhOnco It’s very obvious that a screening MRI brain of asymptomatic ER -ve, or HER-2 +ve mBC patients is useful. Also always do if the patient has lung mets. There’s a correlation.

🎀 BRAIN MRI IN METASTATIC BREAST CANCER TIME TO REWRITE GUIDELINES? 🧠✨ 📊 Up to 50% of HER2⁺ / TNBC MBC patients develop brain mets. Yet, ASCO/NCCN: “Scan only if symptoms.” 🔍 New data challenge that: 🧩 Baseline MRI detects asymptomatic BM in ~25% 🌈 Earlier detection → smaller lesions, more SRS, less WBRT 💊 HER2⁺: early detection enables CNS-active therapy (T-DXd, tucatinib) 🧍‍♀️ 85% patients want screening despite no proven OS benefit 💬 “Waiting for RCTs may not be practical early detection improves QoL, safety & equity.” 🧭 Take-home: Routine brain MRI could shift MBC care from crisis management ➜ proactive intervention. #BreastCancer #BrainMetastases #Oncology @TheBreastJrnl @myesmo @esmo_open @ASCO @OncoAlert @DFCI_BreastOnc 📖 Sammons et al. The Breast 2025. 🔗 doi.org/10.1016/j.brea…

HER eBC management is improving survival but more complex. Here is a proposed algorithm with new advances post @myESMO #ESMO25 What do you think? What would you change? @matteolambe @PTarantinoMD @E_de_Azambuja @stolaney1 @Rodrosb @ElisaAgostinett @ErikaHamilton9 @hoperugo

#ESMO25 Managing HR+/HER2– mBC in 2025 💬An update is likely following the evERA and VIKTORIA-1 trials From Dr. William Gradishar's presentation👇

#ESMO25 💥DESTINY-Breast05 💥 T-DXd vs T-DM1 in residual high-risk HER2+ early BC: ✅️IDFS: 6.2 % vs 12.5 % → HR 0.47 ILD: 9.6 % (2 G5) vs 1.6 %! 💬 T-DXd substantially lowered recurrence risk vs T-DM1 — likely the new post-neoadjuvant standard. Full data eagerly awaited

#ESMO25 OS with first- vs second-line CDK4/6i in HR+/HER2– ABC (SONIA trial) 🔹 mFU 58.5 mo 🔹 OS: 47.9 mo (1L) vs 48.1 mo (2L) 🔹 Trend favoring 1L only in premenopausal pts (HR 0.53) 💬 No significant OS difference — similar outcomes, more toxicity & cost with 1L CDK4/6i?

#ESMO25 DESTINY-Breast11: First results Neoadjuvant T-DXd-THP vs ddAC-THP ✅️pCR: 67.3 vs 56.3 % (Δ +11.2 %) ↪️Benefit in both HR+ (61 vs 52 %) and HR– (83 vs 67 %) EFS trend: HR 0.56 Grade ≥3 AEs: 37 vs 56 %; ILD 4.4 %, LV dysf. 1.9 % New SoC?

There is a sign up at Labour conference saying you must get consent before shaking someone's hand It also says no high fives, fist bumps or hugs unless consent is given either Imagine living your life like this 🤣

The RAS dam has broken! Current trials with KRAS inhibitors in progress from @DavidHongMD @MDAndersonNews #AACRpan25